Prospects for strain-specific immunotherapy in Alzheimer’s disease and tauopathies

Downregulated apoptosis and autophagy after anti-Aβ immunotherapy in Alzheimer's disease

(2018) Claire Paquet et al.   BRAIN PATHOLOGY

Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial

(2017) Petr Novak et al.   LANCET NEUROLOGY

Anti-tau vaccine in Alzheimer's disease: a tentative step

(2017) Francesco Panza et al.   LANCET NEUROLOGY

Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency

(2017) Michael G. Agadjanyan et al.   Molecular Neurodegeneration

TREM2 in Neurodegenerative Diseases

(2017) Taylor R. Jay et al.   Molecular Neurodegeneration

Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease

(2017) Rebecca Sims et al.   NATURE GENETICS

Antibody therapies in CNS diseases

(2017) Per-Ola Freskgård et al.   NEUROPHARMACOLOGY

Cytosolic Fc receptor TRIM21 inhibits seeded tau aggregation

(2017) William A. McEwan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy

(2017) Kiran Yanamandra et al.   Science Translational Medicine

Tau passive immunization inhibits not only tau but also Aβ pathology

(2017) Chun-ling Dai et al.   Alzheimers Research & Therapy

Tau Oligomers: Cytotoxicity, Propagation, and Mitochondrial Damage

(2017) Scott S. Shafiei et al.   Frontiers in Aging Neuroscience

Immunotherapy Targeting Pathological Tau Protein in Alzheimer's Disease and Related Tauopathies

(2017) Einar M. Sigurdsson   JOURNAL OF ALZHEIMERS DISEASE

Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients

(2016) Eric R. Siemers et al.   Alzheimers & Dementia

Toward more predictive genetic mouse models of Alzheimer's disease

(2016) Kristen D. Onos et al.   BRAIN RESEARCH BULLETIN

Potential mechanisms and implications for the formation of tau oligomeric strains

(2016) Julia E. Gerson et al.   CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY

TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance

(2016) Xianyuan Xiang et al.   EMBO Molecular Medicine

Tau-based therapeutics for Alzheimer’s disease: active and passive immunotherapy

(2016) Francesco Panza et al.   Immunotherapy

Affinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy

(2016) Erin E. Congdon et al.   Molecular Neurodegeneration

Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges

(2016) Holger Cynis et al.   Molecular Neurodegeneration

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

(2016) Jeff Sevigny et al.   NATURE

Discovery of Novel Blood-Brain Barrier Targets to Enhance Brain Uptake of Therapeutic Antibodies

(2016) Y. Joy Yu Zuchero et al.   NEURON

Tau Prion Strains Dictate Patterns of Cell Pathology, Progression Rate, and Regional Vulnerability In Vivo

(2016) Sarah K. Kaufman et al.   NEURON

Early changes in CSF sTREM2 in dominantly inherited Alzheimers disease occur after amyloid deposition and neuronal injury

(2016) M. Suarez-Calvet et al.   Science Translational Medicine

Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials

(2016) Rik Vandenberghe et al.   Alzheimers Research & Therapy

Current Research Therapeutic Strategies for Alzheimer’s Disease Treatment

(2016) Jaume Folch et al.   NEURAL PLASTICITY

Specific Targeting of Tau Oligomers in Htau Mice Prevents Cognitive Impairment and Tau Toxicity Following Injection with Brain-Derived Tau Oligomeric Seeds

(2016) Diana L. Castillo-Carranza et al.   JOURNAL OF ALZHEIMERS DISEASE

The triggering receptor expressed on myeloid cells 2 (TREM2) is associated with enhanced inflammation, neuropathological lesions and increased risk for Alzheimer's dementia

(2015) Panos Roussos et al.   Alzheimers & Dementia

Tau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimer’s Disease and Other Tauopathies

(2015) Sulana K. Schroeder et al.   Journal of Neuroimmune Pharmacology

Internalized Tau Oligomers Cause Neurodegeneration by Inducing Accumulation of Pathogenic Tau in Human Neurons Derived from Induced Pluripotent Stem Cells

(2015) M. Usenovic et al.   JOURNAL OF NEUROSCIENCE

Tau Immunotherapy Modulates Both Pathological Tau and Upstream Amyloid Pathology in an Alzheimer's Disease Mouse Model

(2015) D. L. Castillo-Carranza et al.   JOURNAL OF NEUROSCIENCE

The case for rejecting the amyloid cascade hypothesis

(2015) Karl Herrup   NATURE NEUROSCIENCE

Three dimensions of the amyloid hypothesis: time, space and 'wingmen'

(2015) Erik S Musiek et al.   NATURE NEUROSCIENCE

Tau Immunotherapy

(2015) Einar M. Sigurdsson   Neurodegenerative Diseases

Amyloid-β11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials

(2015) Enchi Liu et al.   NEUROLOGY

Immunotherapeutic Approaches for Alzheimer’s Disease

(2015) Thomas Wisniewski et al.   NEURON

Evidence for α-synuclein prions causing multiple system atrophy in humans with parkinsonism

(2015) Stanley B. Prusiner et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer’s disease

(2015) Martin R Farlow et al.   Alzheimers Research & Therapy

COMBINATION THERAPY WITH A PLAQUE-SPECIFIC ABETA ANTIBODY AND BACE INHIBITOR RESULTS IN DRAMATIC PLAQUE LOWERING IN AGED PDAPP TRANSGENIC MICE

(2014) Ronald DeMattos et al.   Alzheimers & Dementia

Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer‘s disease

(2014) Ludovic Collin et al.   BRAIN

Stages and Conformations of the Tau Repeat Domain during Aggregation and Its Effect on Neuronal Toxicity

(2014) Satish Kumar et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Clearing the way for tau immunotherapy in Alzheimer's disease

(2014) Abigail Herrmann et al.   JOURNAL OF NEUROCHEMISTRY

Passive Immunization with Tau Oligomer Monoclonal Antibody Reverses Tauopathy Phenotypes without Affecting Hyperphosphorylated Neurofibrillary Tangles

(2014) D. L. Castillo-Carranza et al.   JOURNAL OF NEUROSCIENCE

Tau deletion impairs intracellular β-amyloid-42 clearance and leads to more extracellular plaque deposition in gene transfer models

(2014) Irina Lonskaya et al.   Molecular Neurodegeneration

Distinct Tau Prion Strains Propagate in Cells and Mice and Define Different Tauopathies

(2014) David W. Sanders et al.   NEURON

p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice

(2014) Ken C. Walls et al.   NEUROSCIENCE LETTERS

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

(2014) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Specificity of Anti-Tau Antibodies when Analyzing Mice Models of Alzheimer's Disease: Problems and Solutions

(2014) Franck R. Petry et al.   PLoS One

First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model

(2014) Eva Kontsekova et al.   Alzheimers Research & Therapy

Active immunotherapy options for Alzheimer’s disease

(2014) Bengt Winblad et al.   Alzheimers Research & Therapy

Amyloid-β and Tau

(2014) George S. Bloom   JAMA Neurology

The formation of tau pore-like structures is prevalent and cell specific: possible implications for the disease phenotypes

(2014) Cristian A Lasagna-Reeves et al.   Acta Neuropathologica Communications

Characterization of tau oligomeric seeds in progressive supranuclear palsy

(2014) Julia E Gerson et al.   Acta Neuropathologica Communications

Molecular Structure of β-Amyloid Fibrils in Alzheimer’s Disease Brain Tissue

(2013) Jun-Xia Lu et al.   CELL

Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation

(2013) Lea Rozenstein-Tsalkovich et al.   EXPERIMENTAL NEUROLOGY

Antibody Uptake into Neurons Occurs Primarily via Clathrin-dependent Fcγ Receptor Endocytosis and Is a Prerequisite for Acute Tau Protein Clearance

(2013) Erin E. Congdon et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Tau pathology and neurodegeneration

(2013) Maria Grazia Spillantini et al.   LANCET NEUROLOGY

Immunotherapy for Alzheimer’s disease: hoops and hurdles

(2013) Cynthia A Lemere   Molecular Neurodegeneration

ApoE4 induces Aβ42, tau, and neuronal pathology in the hippocampus of young targeted replacement apoE4 mice

(2013) Ori Liraz et al.   Molecular Neurodegeneration

Alzheimer disease therapy—moving from amyloid-β to tau

(2013) Ezio Giacobini et al.   Nature Reviews Neurology

Investigating the role of rare heterozygous TREM2 variants in Alzheimer's disease and frontotemporal dementia

(2013) Elise Cuyvers et al.   NEUROBIOLOGY OF AGING

Alzheimer disease in the United States (2010-2050) estimated using the 2010 census

(2013) L. E. Hebert et al.   NEUROLOGY

Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo

(2013) Kiran Yanamandra et al.   NEURON

GWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimer’s Disease

(2013) Carlos Cruchaga et al.   NEURON

Developing Therapeutic Antibodies for Neurodegenerative Disease

(2013) Y. Joy Yu et al.   Neurotherapeutics

Immunotherapy for neurodegenerative diseases: Focus on α-synucleinopathies

(2013) Elvira Valera et al.   PHARMACOLOGY & THERAPEUTICS

Tau Passive Immunotherapy in Mutant P301L Mice: Antibody Affinity versus Specificity

(2013) Cristina d’Abramo et al.   PLoS One

Neuropathological Alterations in Alzheimer Disease

(2013) A. Serrano-Pozo et al.   Cold Spring Harbor Perspectives in Medicine

Tau oligomers and tau toxicity in neurodegenerative disease

(2012) Sarah M. Ward et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Amyloid-β Immunotherapy for Alzheimers Disease

(2012) H.J. Fu et al.   CNS & Neurological Disorders-Drug Targets

Reducing Human Apolipoprotein E Levels Attenuates Age-Dependent A  Accumulation in Mutant Human Amyloid Precursor Protein Transgenic Mice

(2012) N. Bien-Ly et al.   JOURNAL OF NEUROSCIENCE

Soluble A  Promotes Wild-Type Tau Pathology In Vivo

(2012) M. A. Chabrier et al.   JOURNAL OF NEUROSCIENCE

Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study

(2012) Bengt Winblad et al.   LANCET NEUROLOGY

Amyloid Oligomers Exacerbate Tau Pathology in a Mouse Model of Tauopathy

(2012) Maj-Linda B. Selenica et al.   Neurodegenerative Diseases

Variant of TREM2 Associated with the Risk of Alzheimer's Disease

(2012) Thorlakur Jonsson et al.   NEW ENGLAND JOURNAL OF MEDICINE

TREM2 Variants in Alzheimer's Disease

(2012) Rita Guerreiro et al.   NEW ENGLAND JOURNAL OF MEDICINE

National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach

(2011) Thomas J. Montine et al.   ACTA NEUROPATHOLOGICA

Advances in tau-based drug discovery

(2011) Wendy Noble et al.   Expert Opinion on Drug Discovery

Brain Oligomeric β-Amyloid but Not Total Amyloid Plaque Burden Correlates With Neuronal Loss and Astrocyte Inflammatory Response in Amyloid Precursor Protein/Tau Transgenic Mice

(2011) Bibiana DaRocha-Souto et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Engineering the variable region of therapeutic IgG antibodies

(2011) Tomoyuki Igawa et al.   mAbs

Conformation dependent monoclonal antibodies distinguish different replicating strains or conformers of prefibrillar Aβ oligomers

(2011) Rakez Kayed et al.   Molecular Neurodegeneration

Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice

(2011) Cristian A Lasagna-Reeves et al.   Molecular Neurodegeneration

Engaging neuroscience to advance translational research in brain barrier biology

(2011) Edward A. Neuwelt et al.   NATURE REVIEWS NEUROSCIENCE

Preparation and Characterization of Neurotoxic Tau Oligomers

(2010) Cristian A. Lasagna-Reeves et al.   BIOCHEMISTRY

Recent advances in the development of immunotherapies for tauopathies

(2010) Kiren Ubhi et al.   EXPERIMENTAL NEUROLOGY

Immunotherapy Targeting Pathological Tau Prevents Cognitive Decline in a New Tangle Mouse Model

(2010) A. Boutajangout et al.   JOURNAL OF NEUROSCIENCE

Amyloid-β and tau — a toxic pas de deux in Alzheimer's disease

(2010) Lars M. Ittner et al.   NATURE REVIEWS NEUROSCIENCE

Mechanism of amyloid plaque formation suggests an intracellular basis of A  pathogenicity

(2010) R. P. Friedrich et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders

(2009) Bruno Vellas et al.   Current Alzheimer Research

Animal models of Alzheimer's disease and frontotemporal dementia

(2008) Jürgen Götz et al.   NATURE REVIEWS NEUROSCIENCE

Linking Aβ and Tau in Late-Onset Alzheimer's Disease: A Dual Pathway Hypothesis

(2008) Scott A. Small et al.   NEURON